Ignite Creation Date:
2025-12-24 @ 9:57 PM
Ignite Modification Date:
2026-02-24 @ 10:52 AM
Study NCT ID:
NCT03831932
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-19
First Post:
2019-02-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-03-16
Start Date Type:
ACTUAL
Primary Completion Date:
2024-06-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-03-14
Completion Date Type:
ESTIMATED
First Submit Date:
2019-02-05
First Submit QC Date:
None
Study First Post Date:
2019-02-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-06-10
Results First Submit QC Date:
None
Results First Post Date:
2025-06-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-18
Last Update Post Date:
2025-09-19
Last Update Post Date Type:
ESTIMATED